Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer
Author:
Affiliation:
1. University of California, Irvine Medical Center, Orange, CA, USA
Funder
Ruth L. Kirschstein NRSA Institutional Training
Publisher
Informa UK Limited
Subject
Pharmacology,Toxicology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/17425255.2018.1461838
Reference38 articles.
1. Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease
2. OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
3. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
4. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
5. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An Updated Comprehensive Pharmacovigilance Study of Drug‐Induced Thrombocytopenia Based on FDA Adverse Event Reporting System Data;The Journal of Clinical Pharmacology;2024-01-05
2. Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting;Pharmaceuticals;2023-09-06
3. Niraparib (Zejula), A Small Molecule, PARP1/2 Inhibitor for Treating Breast, Ovarian, and Pancreatic Cancers;Current Drug Synthesis;2022-09-22
4. Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells;Journal of the American Society for Mass Spectrometry;2021-12-27
5. Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases;Life Sciences;2021-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3